Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy by Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao

Subjects: “…HER2-positive…”
Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

Subjects: Get full text

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer by Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Claudia Chiodoni, Paolo Toneguzzo, Viola Regondi, Paola A. Corsetto, Filippo Pietrantonio, Serena Mazzucchelli, Fabio Corsi, Antonio Belfiore, Antonio Vingiani, Giancarlo Pruneri, Francesca Ligorio, Mario P. Colombo, Elda Tagliabue, Claudio Tripodo, Claudio Vernieri, Tiziana Triulzi, Serenella M. Pupa

Subjects: “…HER2…”
Get full text

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Subjects: Get full text

LRP1 involvement in FHIT-regulated HER2 signaling in non-small cell lung cancer by Théophile Ponchel, Emma Loeffler, Julien Ancel, Audrey Brisebarre, Nathalie Lalun, Véronique Dalstein, Anne Durlach, Gaëtan Deslée, Stéphane Dedieu, Myriam Polette, Béatrice Nawrocki-Raby

Subjects: Get full text

The optimal treatment of invasive ductal and lobular carcinoma occurring at the same time needs to be established by Supriya Peshin, Rafi Iftekher, Rabia Iqbal, Shagun Singh, Moka Nagaishwarya

Subjects: Get full text

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs by Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng

Subjects: Get full text

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics by Xudong Zhang, Hanqing Kong, Xiaoxue Liu, Qingxiang Li, Xinran Fang, Junjia Wang, Zihao Qin, Nana Hu, Jiawei Tian, Hao Cui, Lei Zhang

Subjects: “…HER2…”
Get full text

Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch) by Dina Labib, Mark Haykowsky, Emer Sonnex, John R. Mackey, Richard B. Thompson, D. Ian Paterson, Edith Pituskin

Subjects: “…HER2 therapy…”
Get full text

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab t... by Huanhuan Li, Chao Ren, Donghai Cui, Tao Wu, Zhiyong Nie

Subjects: “…HER-2…”
Get full text

Molecular characterization and potential therapeutic roles of miR125a in HER-2 positive gastric cancer by Afraa Mamoori, Zena Hasan Sahib, Haider Alkafaji

Subjects: Get full text

A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation ther... by Jing Yang, Meng-Yun Zhou, Bo Yu, Qing Lin, Yuan Yao, Hua-Ling Wu, Qi-Wei Zhu, Ming Ye, Hua-Ying Xie, Jian-Wei Wu, Gang Cai, Rong Cai, Wei-Xiang Qi, Jia-Yi Chen, Lu Cao

Subjects: Get full text

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer by Hanghang Ma, Jianbin Li

Subjects: Get full text

PhyIndBC: Development of a machine learning tool for screening of potential breast cancer inhibitors from phytochemicalsGitHub by Agneesh Pratim Das, Subhash M. Agarwal

Subjects: Get full text

Establishment of a Rapid and Convenient Fluoroimmunoassay Platform Using Antibodies Against PDL1 and HER2 by Ji Eun Choi, Hanool Yun, Hee-Jin Jeong

Subjects: Get full text

Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy by Yatong Chen, Fei Luo, Tingji Zhang, Jian Li

Subjects: “…HER2…”
Get full text

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management by Xinpei Deng, Yixuan Yan, Zekai Zhan, Jindong Xie, Hailin Tang, Yutian Zou, Jian Tu, Peng Liu

Subjects: “…anti‐HER2 therapy…”
Get full text

Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years by Frederik K. Palshof, Lina S. Mørch, Maj-Britt R. Jensen, Hans H. Storm, Niels Kroman, Tove H.F. Tvedskov

Subjects: Get full text

Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments by Amit Verma, Vikas Pandey, Catherine Sherry, Taylor Humphrey, Christopher James, Kailie Matteson, Jason T. Smith, Alena Rudkouskaya, Xavier Intes, Margarida Barroso

Subjects: Get full text

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by Amelia C. McCue, Stephen J. Demarest, Karen J. Froning, Michael J. Hickey, Stephen Antonysamy, Brian Kuhlman

Subjects: Get full text